B2RAD Translational Medicine Study
Study Details
Study Description
Brief Summary
Recent advances in understanding the molecular and cellular pathology of many diseases have resulted in direct benefit to today's patients. The translational research studies that have led to these advances relied on an integrated model of clinical and non-clinical laboratory investigations based on the analysis of human biospecimens that lead directly to drug discovery, drug validation, novel detection assays, and prognostic marker discovery. Translational research provides a unique mechanism to address questions specific to particular tumor or other disease types, biological modifiers and/or mechanisms of action that are essential for the advancement of healthcare. Specimens are to be collected from subjects who are having or have had a surgical or medical procedure (such as fluid or tissue removed, a biopsy or a blood or bone marrow draw). Any subject in which the primary diagnosis of disease was made within the DHR Health System and Any subject choosing to give consent for participation will be included
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Biobank Specimens are to be collected from subjects who are having or have had a surgical or medical procedure (such as fluid or tissue removed, a biopsy or a blood or bone marrow draw). Any subject in which the primary diagnosis of disease was made within the DHR Health System and Any subject choosing to give consent for participation will be included. |
Other: Specimen Collection
collection of diseased and non-diseased tissue, blood, and other body fluids
|
Outcome Measures
Primary Outcome Measures
- Collection of diseased and non-diseased tissue, blood, and other body fluids [once]
Collection of diseased and non-diseased tissue, blood, and other body fluids to establish a biobank to evaluate all potential clinically relevant alterations in the diseased cells, cellular components and disease biomarkers. The methods used to identify these alterations include: 1) Creation of novel disease and normal cell lines; 2) Molecular analysis; 3) Protein analysis; and 4) other cellular analyses. These methods may be employed immediately after obtaining the biologic material or at a future date after samples have been stored in a bank.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Any subject choosing to give consent for participation will be included.
-
Any subject in which the primary diagnosis of cancer was made at the DHR Health System.
Exclusion Criteria:
-
Any subject deemed unable to provide legally effective consent.
-
Any pediatric subject where the subject does not freely give his or her assent or where his or her parent/guardian does not give consent.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | DHR Health Institute for Research and Development | Edinburg | Texas | United States | 78539 |
| 2 | DHR Health | Edinburg | Texas | United States | 78539 |
Sponsors and Collaborators
- Sohail Rao
Investigators
- Principal Investigator: Sohail Rao, MD, DHR Heath Institute for Research and Development
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1551551